{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T14:04:52Z","timestamp":1773497092466,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.clinre.2020.06.013","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T08:20:06Z","timestamp":1594110006000},"page":"101487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-term outcome of patients with difficult-to-treat autoimmune hepatitis receiving mycophenolate mofetil"],"prefix":"10.1016","volume":"45","author":[{"given":"Rodrigo","family":"Liberal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme","family":"Macedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clinre.2020.06.013_bib0180","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"Journal of hepatology"},{"key":"10.1016\/j.clinre.2020.06.013_bib0185","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jaut.2012.11.002","article-title":"Autoimmune hepatitis: a comprehensive review","volume":"41","author":"Liberal","year":"2013","journal-title":"Journal of autoimmunity"},{"issue":"4","key":"10.1016\/j.clinre.2020.06.013_bib0190","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL Clinical Practice Guidelines: Autoimmune hepatitis","volume":"63","author":"European Association for the Study of the L.","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2020.06.013_bib0195","article-title":"Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases","author":"Mack","year":"2019","journal-title":"Hepatology"},{"issue":"158","key":"10.1016\/j.clinre.2020.06.013_bib0200","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/oxfordjournals.qjmed.a067264","article-title":"Controlled prospective trial of corticosteroid therapy in active chronic hepatitis","volume":"40","author":"Cook","year":"1971","journal-title":"Q J Med"},{"issue":"7806","key":"10.1016\/j.clinre.2020.06.013_bib0205","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(73)92125-9","article-title":"Controlled trial of prednisone and azathioprine in active chronic hepatitis","volume":"1","author":"Murray-Lyon","year":"1973","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clinre.2020.06.013_bib0210","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0016-5085(19)33223-8","article-title":"Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis","volume":"63","author":"Soloway","year":"1972","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.clinre.2020.06.013_bib0215","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.clinre.2020.06.013_bib0220","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/hep.510250308","article-title":"Autoimmune hepatitis in childhood: a 20-year experience","volume":"25","author":"Gregorio","year":"1997","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.clinre.2020.06.013_bib0225","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/lt.23704","article-title":"Liver transplantation and autoimmune liver diseases","volume":"19","author":"Liberal","year":"2013","journal-title":"Liver Transpl"},{"issue":"8","key":"10.1016\/j.clinre.2020.06.013_bib0230","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2036.2010.04241.x","article-title":"Review article: the modern management of autoimmune hepatitis","volume":"31","author":"Yeoman","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinre.2020.06.013_bib0235","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-065X.1993.tb00652.x","article-title":"Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil","volume":"136","author":"Allison","year":"1993","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.clinre.2020.06.013_bib0240","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/cei.12956","article-title":"Immunosuppressive drugs affect interferon (IFN)-gamma and programmed cell death 1 (PD-1) kinetics in patients with newly diagnosed autoimmune hepatitis","volume":"189","author":"Grant","year":"2017","journal-title":"Clin Exp Immunol"},{"issue":"1 Suppl","key":"10.1016\/j.clinre.2020.06.013_bib0245","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1097\/01.tp.0000187133.53916.8f","article-title":"Indications of mycophenolate mofetil in liver transplantation","volume":"80","author":"Klupp","year":"2005","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.clinre.2020.06.013_bib0250","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/TP.0b013e31822d880d","article-title":"Mycophenolate mofetil monotherapy in liver transplantation: 5-year follow-up of a prospective randomized trial","volume":"92","author":"Schmeding","year":"2011","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.clinre.2020.06.013_bib0255","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.clinre.2020.06.013_bib0260","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2010.09.002","article-title":"Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue","volume":"54","author":"Boberg","year":"2011","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.clinre.2020.06.013_bib0265","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.clinre.2020.06.013_bib0270","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0168-8278(00)80286-X","article-title":"Mycophenolate mofetil--a new treatment for autoimmune hepatitis?","volume":"33","author":"Dhawan","year":"2000","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.clinre.2020.06.013_bib0275","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0168-8278(00)80271-8","article-title":"Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine","volume":"33","author":"Richardson","year":"2000","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.clinre.2020.06.013_bib0280","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1155\/2004\/504591","article-title":"Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy","volume":"18","author":"Devlin","year":"2004","journal-title":"Can J Gastroenterol"},{"issue":"9","key":"10.1016\/j.clinre.2020.06.013_bib0285","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/01.mcg.0000177260.72692.e8","article-title":"Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease","volume":"39","author":"Czaja","year":"2005","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"10.1016\/j.clinre.2020.06.013_bib0290","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1478-3231.2005.01107.x","article-title":"Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus","volume":"25","author":"Chatur","year":"2005","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.clinre.2020.06.013_bib0295","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.cgh.2007.02.030","article-title":"Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy","volume":"5","author":"Inductivo-Yu","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.clinre.2020.06.013_bib0300","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cgh.2008.04.006","article-title":"A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis","volume":"6","author":"Hlivko","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.clinre.2020.06.013_bib0305","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1111\/j.1572-0241.2008.02180.x","article-title":"Mycophenolate mofetil as second line therapy in autoimmune hepatitis?","volume":"103","author":"Hennes","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.clinre.2020.06.013_bib0310","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1007\/s10620-008-0632-0","article-title":"Mycophenolate mofetil for autoimmune hepatitis: a single practice experience","volume":"54","author":"Wolf","year":"2009","journal-title":"Dig Dis Sci"},{"issue":"10","key":"10.1016\/j.clinre.2020.06.013_bib0315","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1155\/2010\/891252","article-title":"Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy","volume":"24","author":"Sharzehi","year":"2010","journal-title":"Can J Gastroenterol"},{"issue":"3","key":"10.1016\/j.clinre.2020.06.013_bib0320","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2036.2011.04727.x","article-title":"The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes","volume":"34","author":"Baven-Pronk","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.clinre.2020.06.013_bib0325","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cgh.2017.09.063","article-title":"Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy","volume":"16","author":"Roberts","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.clinre.2020.06.013_bib0330","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/apt.13584","article-title":"A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis","volume":"43","author":"Zachou","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.clinre.2020.06.013_bib0335","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.cgh.2017.06.001","article-title":"Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis","volume":"15","author":"Efe","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.clinre.2020.06.013_bib0340","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/apt.15157","article-title":"Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis","volume":"49","author":"Santiago","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.clinre.2020.06.013_bib0345","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.dld.2018.10.004","article-title":"Mycophenolate mofetil treatment in patients with autoimmune hepatitis failing standard therapy with prednisolone and azathioprine","volume":"51","author":"Giannakopoulos","year":"2019","journal-title":"Dig Liver Dis"},{"issue":"4","key":"10.1016\/j.clinre.2020.06.013_bib0350","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/hep.25760","article-title":"Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis","volume":"56","author":"Dhaliwal","year":"2012","journal-title":"Hepatology"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740120301820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740120301820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:31:26Z","timestamp":1761895886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740120301820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S2210740120301820"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2020.06.013","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcome of patients with difficult-to-treat autoimmune hepatitis receiving mycophenolate mofetil","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2020.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101487"}}